A single pill to treat postmenopausal hypertension? Not yet

Current Topics in Medicinal Chemistry

Volumn 11, Issue 13, 2011, Pages 1736-1741

  Yanes, Licy L ^a,b   Romero, Damian G ^a   Iliescu, Radu ^c   Reckelhoff, Jane F ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Aldosterone; Angiotensin II; Blood pressure; Endothelin; Menopause; Sex steroids sympathetic; Visceral obesity

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANDROGEN RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSINOGEN; ATRASENTAN; CANDESARTAN; CHOLESTEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYTOCHROME P450; DROSPERIDONE; ENDOTHELIN; ESTRADIOL; ESTROGEN; GESTAGEN; LOSARTAN; MINERALOCORTICOID ANTAGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; ORAL CONTRACEPTIVE AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE P60; SPIRONOLACTONE; STEROIDOGENIC ACUTE REGULATORY PROTEIN; TESTOSTERONE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALDOSTERONE RELEASE; ARTERIAL PRESSURE; ARTICLE; BAROREFLEX SENSITIVITY; BLOOD PRESSURE VARIABILITY; CALCIUM CELL LEVEL; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DOWN REGULATION; FEMALE TO MALE TRANSSEXUAL; GENOMICS; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY INJURY; MENOPAUSAL SYNDROME; NONHUMAN; OVARIECTOMY; OVARY POLYCYSTIC DISEASE; PLASMA RENIN ACTIVITY; POSTMENOPAUSAL HYPERTENSION; PRESSORECEPTOR REFLEX; PROTEIN EXPRESSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; SIDE EFFECT; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; UPREGULATION; VASCULAR RESISTANCE; ZONA GLOMERULOSA;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTENSION; MALE; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 79959925811     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802611796117667     Document Type: Article

References (58)

1. Burt, V.L.; Whelton, P.; Roccella, E.J.; Brown, C.; Cutler, J.A.; Higgins, M.; Horan, M.J.; Labarthe, D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension, 1995, 25(3), 305-313.
2. Wiinberg, N.; Hoegholm, A.; Christensen, H R.; Bang, L. E.; Mikkelsen, K.L.; Nielsen, P.E.; Svendsen, T.L.; Kampmann, J. P.; Madsen, N.H.; Bentzon, M.W. 24-h ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am. J. Hypertens, 1995, 8(10 Pt 1), 978-986.
3. Kannel, W.B. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J. Gend Specif. Med., 2002, 5(2), 27-37.
4. Wassertheil-Smoller, S.; Anderson, G.; Psaty, B.M.; Black, H.R.; Manson, J.; Wong, N.; Francis, J.; Grimm, R.; Kotchen, T.; Langer, R.; Lasser, N. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension, 2000, 36(5), 780-789.
5. Ong, K.L.; Tso, A.W.; Lam, K.S.; Cheung, B.M. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension, 2008, 51(4), 1142-1148.
6. Hall, J.E.; Brands, M.W.; Henegar, J.R. Angiotensin II and longterm arterial pressure regulation: the overriding dominance of the kidney. J. Am. Soc. Nephrol., 1999, 10(Suppl 12), S258-265.
7. Hall, J.E.; Guyton, A.C.; Brands, M.J. Control of sodium excretion and arterial pressure by intrarenal mechanisms and the reninangiotensin system. In: Hypertension: Pathophysiology, Diagnosis, and Management. Laragh JH, Brenner BM, Eds. Raven Press: New York; 1995; pp. 1451-1475.
8. Giacche, M.; Vuagnat, A.; Hunt, S.C.; Hopkins, P.N.; Fisher, N.D.; Azizi, M.; Corvol, P.; Williams, G.H.; Jeunemaitre, X. Aldosterone stimulation by angiotensin II: influence of gender, plasma renin, and familial resemblance. Hypertension, 2000, 35(3), 710-716.
9. Trenkwalder, P.; James, G.D.; Laragh, J.H.; Sealey, J.E. Plasma renin activity and plasma prorenin are not suppressed in hypertensives surviving to old age. Am. J. Hypertens., 1996, 9(7), 621-627.
10. Yanes, L.L.; Romero, D.G.; Iles, J.W.; Iliescu, R.; Gomez-Sanchez, C.; Reckelhoff, J.F. Sexual dimorphism in the renin-angiotensin system in aging spontaneously hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2006, 291(2), R383-390.
11. Nickenig, G.; Baumer, A.T.; Grohe, C.; Kahlert, S.; Strehlow, K.; Rosenkranz, S.; Stablein, A.; Beckers, F.; Smits, J.F.; Daemen, M.J.; Vetter, H.; Bohm, M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998, 97(22), 2197-2201.
12. Owonikoko, T.K.; Fabucci, M.E.; Brown, P.R.; Nisar, N.; Hilton, J.; Mathews, W.B.; Ravert, H.T.; Rauseo, P.; Sandberg, K.; Dannals, R.F.; Szabo, Z. In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET. J. Nucl. Med., 2004, 45(1), 94-100.
13. Rogers, J.L.; Mitchell, A.R.; Maric, C.; Sandberg, K.; Myers, A.; Mulroney, S.E. Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292(2), R794-799.
14. Klett, C.; Hellmann, W.; Hackenthal, E.; Ganten, D. Modulation of tissue angiotensinogen gene expression by glucocorticoids, estrogens, and androgens in SHR and WKY rats. Clin. Exp. Hypertens., 1993, 15(4), 683-708.
15. Reckelhoff, J.F.; Zhang, H.; Srivastava, K. Gender differences in development of hypertension in spontaneously hypertensive rats: role of the renin-angiotensin system. Hypertension, 2000, 35(1 Pt 2), 480-483.
16. Fernandez-Vega, F.; Abellan, J.; Vegazo, O.; De Vinuesa, S.G.; Rodriguez, J.C.; Maceira, B.; de Castro, S.S.; Nicolas, R.R.; Luno, J. Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy. Kidney Int. Suppl., 2002, (82), S36-41.
17. Stewart, P.M. The Adrenal Cortex. In: Williams Textbook of Endocrinology. Larsen PR, Kronenberg, H.M.; Melmed, S.; Polonsky, K.S. Eds. Elsevier: Philadelphia; 2003; pp. 491-551.
18. Connell, J.M.; Davies, E. The new biology of aldosterone. J. Endocrinol., 2005, 186(1), 1-20.
19. White, W.B.; Hanes, V.; Chauhan, V.; Pitt, B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension, 2006, 48(2), 246-253.
20. Negulescu, O.; Bognar, I.; Lei, J.; Devarajan, P.; Silbiger, S.; Neugarten, J. Estradiol reverses TGF-beta1-induced mesangial cell apoptosis by a casein kinase 2-dependent mechanism. Kidney Int., 2002, 62(6), 1989-1998.
21. Alvarez, A.; Hermenegildo, C.; Issekutz, A.C.; Esplugues, J.V.; Sanz, M. J. Estrogens inhibit angiotensin II-induced leukocyteendothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation. Circ. Res., 2002, 91(12), 1142-1150.
22. Mori, M.; Tsukahara, F.; Yoshioka, T.; Irie, K.; Ohta, H. Suppression by 17beta-estradiol of monocyte adhesion to vascular endothelial cells is mediated by estrogen receptors. Life Sci., 2004, 75(5), 599-609.
23. Rodriguez, E.; Lopez, R.; Paez, A.; Masso, F.; Montano, L.F. 17Beta-estradiol inhibits the adhesion of leukocytes in TNF-alpha stimulated human endothelial cells by blocking IL-8 and MCP-1 secretion, but not its transcription. Life Sci., 2002, 71(18), 2181-2193.
24. Hsia, J.; Langer, R.D.; Manson, J.E.; Kuller, L.; Johnson, K.C.; Hendrix, S.L.; Pettinger, M.; Heckbert, S.R.; Greep, N.; Crawford, S.; Eaton, C.B.; Kostis, J.B.; Caralis, P.; Prentice, R. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch. Intern. Med., 2006, 166(3), 357-365.
25. Oestreicher, E.M.; Guo, C.; Seely, E.W.; Kikuchi, T.; Martinez-Vasquez, D.; Jonasson, L.; Yao, T.; Burr, D.; Mayoral, S.; Roubsanthisuk, W.; Ricchiuti, V.; Adler, G.K. Estradiol increases proteinuria and angiotensin II type 1 receptor in kidneys of rats receiving L-NAME and angiotensin II. Kidney Int., 2006, 70(10), 1759-1768.
26. Ribstein J, Halimi JM, du Cailar G, Mimran A. Renal characteristics and effect of angiotensin suppression in oral contraceptive users. Hypertension, 1999, 33(1), 90-95.
27. Boyd, W.N.; Burden, R.P.; Aber, G.M. Intrarenal vascular changes in patients receiving oestrogen-containing compounds--a clinical, histological and angiographic study. Q. J. Med., 1975, 44(175), 415-431.
28. Parati, G.; Di Rienzo, M.; Mancia, G. Dynamic modulation of baroreflex sensitivity in health and disease. Ann. N.Y. Acad. Sci., 2001, 940: 469-487.
29. Monahan, K.D.; Dinenno, F.A.; Tanaka, H.; Clevenger, C.M.; DeSouza, C.A.; Seals, D.R. Regular aerobic exercise modulates age-associated declines in cardiovagal baroreflex sensitivity in healthy men. J. Physiol., 2000, 529, Pt 1: 263-271.
30. Minami, N.; Mori, N.; Nagasaka, M.; Ito, O.; Ogawa, M.; Kurosawa, H.; Kanazawa, M.; Kohzuki, M. Exercise training fails to modify arterial baroreflex sensitivity in ovariectomized female rats. Tohoku J. Exp. Med., 2007, 211(4), 339-345.
31. Lavi, S.; Nevo, O.; Thaler, I.; Rosenfeld, R.; Dayan, L.; Hirshoren, N.; Gepstein, L.; Jacob, G. Effect of aging on the cardiovascular regulatory systems in healthy women. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007, 292(2), R788-793.
32. Huikuri, H.V.; Pikkujamsa, S.M.; Airaksinen, K.E.; Ikaheimo, M.J.; Rantala, A.O.; Kauma, H.; Lilja, M.; Kesaniemi, Y.A. Sexrelated differences in autonomic modulation of heart rate in middle-aged subjects. Circulation, 1996, 94(2), 122-125.
33. El-Mas, M.M.; Abdel-Rahman, A.A. Estrogen enhances baroreflex control of heart rate in conscious ovariectomized rats. Can. J. Physiol. Pharmacol., 1998, 76(4), 381-386.
34. Oelkers, W.; Foidart, J. M.; Dombrovicz, N.; Welter, A.; Heithecker, R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the reninaldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J. Clin. Endocrinol. Metab., 1995, 80(6), 1816-1821.
35. Riegger, G.A.; Bouzo, H.; Petr, P.; Munz, J.; Spacek, R; Pethig, H.; von Behren, V.; George, M.; Arens, H. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, tolerability, response to exercise trial of candesartan cilexetil in heart failure (STRETCH) investigators. Circulation, 1999, 100(22), 2224-2230.
36. van Kesteren, P. J.; Kooistra, T.; Lansink, M.; van Kamp, G.J.; Asscheman, H.; Gooren, L.J.; Emeis, J.J.; Vischer, U.M.; Stehouwer, C. D The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb. Haemost., 1998, 79(5), 1029-1033.
37. Montezano, A.C.; Callera, G.E.; Mota, A.L.; Fortes, Z.B.; Nigro, D.; Carvalho, M.H.; Zorn, T.M.; Tostes, R.C. Endothelin-1 contributes to the sexual differences in renal damage in DOCA-salt rats. Peptides, 2005, 26(8), 1454-1462.
38. Muller, V.; Losonczy, G.; Heemann, U.; Vannay, A.; Fekete, A.; Reusz, G.; Tulassay, T.; Szabo, A.J. Sexual dimorphism in renal ischemia-reperfusion injury in rats: possible role of endothelin. Kidney Int., 2002, 62(4), 1364-1371.
39. Gross, M.L.; Adamczak, M.; Rabe, T.; Harbi, N.A.; Krtil, J.; Koch, A.; Hamar, P.; Amann, K.; Ritz, E. Beneficial effects of estrogens on indices of renal damage in uninephrectomized SHRsp Rats. J. Am. Soc. Nephrol., 2004, 15(2), 348-358.
40. Yanes, L.L.; Romero, D.G.; Cucchiarelli, V.E.; Fortepiani, L.A.; Gomez-Sanchez, C. E.; Santacruz, F.; Reckelhoff, J.F. Role of endothelin in mediating postmenopausal hypertension in a rat model. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 288(1), R229-233.
41. Alexander, B.T.; Cockrell, K.L.; Rinewalt, A. N.; Herrington, J.N.; Granger, J.P. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 280(5), R1388-1392.
42. Esler, M.; Straznicky, N.; Eikelis, N.; Masuo, K.; Lambert, G.; Lambert, E. Mechanisms of sympathetic activation in obesityrelated hypertension. Hypertension, 2006, 48(5), 787-796.
43. Quinkler, M.; Bumke-Vogt, C.; Meyer, B.; Bahr, V.; Oelkers, W.; Diederich, S. The human kidney is a progesterone-metabolizing and androgen-producing organ. J. Clin. Endocrinol. Metab., 2003, 88(6), 2803-2809.
44. Elliot, S.J.; Berho, M.; Korach, K.; Doublier, S.; Lupia, E.; Striker, G.E.; Karl, M. Gender-specific effects of endogenous testosterone: female alpha-estrogen receptor-deficient C57Bl/6J mice develop glomerulosclerosis. Kidney Int., 2007, 72(4), 464-472.
45. Baltatu, O.; Cayla, C.; Iliescu, R.; Andreev, D.; Bader, M. Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats. Hypertension, 2003, 41(3 Pt 2), 830-833.
46. Fortepiani, L.A.; Zhang, H.; Racusen, L.; Roberts, L. J2nd.; Reckelhoff, J.F. Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rats. Hypertension, 2003, 41(3 Pt 2), 640-645.
47. Roy, A.K.; Lavrovsky, Y.; Song, C.S.; Chen, S.; Jung, M.H.; Velu, N.K.; Bi, B.Y.; Chatterjee, B. Regulation of androgen action. Vitam. Horm., 1999, 55, 309-352.
48. Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol. Endocrinol., 2002, 16(10), 2181-2187.
49. Boonyaratanakornkit, V.; Edwards, D.P. Receptor mechanisms mediating non-genomic actions of sex steroids. Semin. Reprod. Med., 2007, 25(3), 139-153.
50. Migliaccio, A.; Castoria, G.; Di Domenico, M.; de Falco, A.; Bilancio, A.; Lombardi, M.; Barone, M.V.; Ametrano, D.; Zannini, M.S.; Abbondanza, C.; Auricchio, F. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J., 2000, 19(20), 5406-5417.
51. Kousteni, S.; Bellido, T.; Plotkin, L.I.; O'Brien, C.A.; Bodenner, D.L.; Han, L.; Han, K.; DiGregorio, G.B.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S.; Roberson, P.K.; Weinstein, R.S.; Jilka, R.L.; Manolagas, S.C. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell, 2001, 104(5), 719-730.
52. Guo, Z.; Benten, W.P.; Krucken, J.; Wunderlich, F. Nongenomic testosterone calcium signaling. Genotropic actions in androgen receptor-free macrophages. J. Biol. Chem., 2002, 277(33), 29600-29607.
53. Sun, M.; Yang, L.; Feldman, R.I.; Sun, X.M.; Bhalla, K.N.; Jove, R.; Nicosia, S.V.; Cheng, J.Q. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J. Biol. Chem., 2003, 278(44), 42992-43000.
54. Nguyen, T.V.; Yao, M.; Pike, C.J. Androgens activate mitogenactivated protein kinase signaling: role in neuroprotection. J. Neurochem., 2005, 94(6), 1639-1651.
55. Sun, Y.H.; Gao, X.; Tang, Y.J.; Xu, C.L.; Wang, L.H. Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells. J. Androl., 2006, 27(5), 671-678.
56. Psaty, B.M.; Heckbert, S.R.; Koepsell, T.D.; Siscovick, D.S.; Raghunathan, T.E.; Weiss, N.S.; Rosendaal, F.R.; Lemaitre, R.N.; Smith, N.L.; Wahl, P.W.; Wagner, E.H.; Furberg, C.D. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA, 1995, 274(8), 620-625.
57. Furberg, C.D.; Psaty, B.M.; Meyer, J.V. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation, 1995, 92(5), 1326-1331.
58. Griffin, K.A.; Picken, M.M.; Bidani, A.K. Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J. Clin. Invest., 1995, 96(2), 793-800.